Skip to main content
Jared Seehafer

Jared Seehafer

Search complete. 5 mentions across 5 episodes found for "Jared Seehafer".

Sep 16, 2026

NYT

NYT

9.16.26

Sep 16 · 1 Mention

Dawn FlickingerNARRATOR
25:52
He laid out the federal overhaul needed to deploy them, which included appointing a person at the FDA to focus specifically on artificial intelligence.
Dawn FlickingerNARRATOR
26:02
Last week, the health department did just that, announcing that it had elevated Jared Seehafer, a former tech entrepreneur, to a newly created post of deputy commissioner for technology and artificial intelligence.
Dawn FlickingerNARRATOR
26:18
Mr. Seehafer, a Political appointee who has been at the agency about a year has been described by people who worked with him as wanting to pare back the agency's oversight of medical AI.
Dawn FlickingerNARRATOR
26:31
Mr. C. Hafer's appointment drew notice in Silicon Valley investment circles.
Wayne PinesHOST
1:44
Kareem Mikhail has been named the new permanent director of CBER Biologics.
Wayne PinesHOST
1:51
And Jared Seehafer has been named the first ever deputy commissioner for technology, and artificial intelligence.
Wayne PinesHOST
2:01
We don't know exactly what that position entails, but we will find out because AI is going to be on all of our agendas in the coming months and years and decades.
Wayne PinesHOST
2:15
It's good to have permanent leadership in CEDAR and CBER and to have the kind of stability that AI That implies.
Derrick GingeryHOST
11:05
Mm-hmm.
Derrick GingeryHOST
11:09
I know it's kind of outside of the, uh, the realm of, of this podcast, uh, which is, uh, prescription drugs, but, um, they, they also named, uh, uh, Jared Seehafer as the deputy commissioner for technology and AI, which, you know, has kind of a, you know, uh, tangential, um, you know, connection to the drug side.
Derrick GingeryHOST
11:30
Um, but, you know, because in part, because that's just a role that's going to touch everybody just about at the agency.
Derrick GingeryHOST
11:37
Um, You know, as more attention gets paid to AI, you know, whether it be through the, you know, the tools that FDA is implementing to help with reviews or, you know, the uses in drug development and so forth, or if, you know, like if you believe the statements of some people earlier this week that they are going to, you know, end the human race in decade, you know, it seems kind of like an important, really growing, important position, you know, as a, you know, for whatever reasons you probably could think of based on what I just said.
Derrick GingeryHOST
11:05
Mm-hmm.
Derrick GingeryHOST
11:09
I know it's kind of outside of the, uh, the realm of, of this podcast, uh, which is, uh, prescription drugs, but, um, they, they also named, uh, uh, Jared Seehafer as the deputy commissioner for technology and AI, which, you know, has kind of a, you know, uh, tangential, um, you know, connection to the drug side.
Derrick GingeryHOST
11:30
Um, but, you know, because in part, because that's just a role that's going to touch everybody just about at the agency.
Derrick GingeryHOST
11:37
Um, You know, as more attention gets paid to AI, you know, whether it be through the, you know, the tools that FDA is implementing to help with reviews or, you know, the uses in drug development and so forth, or if, you know, like if you believe the statements of some people earlier this week that they are going to, you know, end the human race in decade, you know, it seems kind of like an important, really growing, important position, you know, as a, you know, for whatever reasons you probably could think of based on what I just said.
Sydney LupkinCORRESPONDENT
2:44
Finally, the agency created a new position, Deputy Commissioner for Technology and Artificial Intelligence.
Sydney LupkinCORRESPONDENT
2:50
Jared Seehafer, who spent most of his career in the private sector, will lead technology, software, and AI.
Sydney LupkinCORRESPONDENT
2:56
Sydney Lupkin, NPR News.
Giles SnyderHOST
2:57
This is NPR.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.